Good Life Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Good Life Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-322	Closed	-$204K	–	530
2025 Q1	$204K	Buy	322 +18	+6%	+$12.4K	0.01%	467
2024 Q4	$217K	Sell	304 -80	-21%	-$67.1K	0.02%	442
2024 Q3	$404K	Buy	384 +144	+60%	+$160K	0.02%	394
2024 Q2	$252K	Buy	240 +6	+3%	+$5.82K	0.02%	390
2024 Q1	$225K	Hold	234	–	–	0.02%	402
2023 Q4	$206K	Buy	+234	New	+$193K	0.02%	405
2022 Q2	–	Sell	-3,288	Closed	-$2.3M	–	387
2022 Q1	$2.3M	Buy	3,288 +142	+5%	+$89.8K	0.29%	69
2021 Q4	$1.99M	Buy	3,146 +87	+3%	+$53.5K	0.24%	78
2021 Q3	$1.85M	Buy	+3,059	New	+$1.9M	0.25%	81

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Good Life Advisors's REGN Position: Q2 2025 in Review

Good Life Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 322 shares — an estimated $204K sold.

Good Life Advisors first reported a position in REGN in Q3 2021 and held it in 9 quarters. The position peaked at $2.3M in Q1 2022. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Good Life Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Good Life Advisors sold 322 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $204K.
Good Life Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Good Life Advisors's Regeneron Pharmaceuticals position peaked at $2.3M in Q1 2022.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.